These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
254 related items for PubMed ID: 21171912
1. Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Zhang F, Dong L, Qian J, Ge J. Ann Med; 2011 Feb; 43(1):75-9. PubMed ID: 21171912 [Abstract] [Full Text] [Related]
4. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A, LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators. J Am Coll Cardiol; 2009 May 12; 53(19):1760-8. PubMed ID: 19422982 [Abstract] [Full Text] [Related]
9. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E. J Am Coll Cardiol; 2011 Jun 28; 58(1):11-8. PubMed ID: 21514083 [Abstract] [Full Text] [Related]
10. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS, Ying SW, Cutlip DE, Stone GW. Am Heart J; 2013 Dec 28; 166(6):1035-42. PubMed ID: 24268218 [Abstract] [Full Text] [Related]
11. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. Wang Q, Pierson W, Sood P, Bol C, Cannon L, Gordon P, Saucedo J, Sudhir K. J Interv Cardiol; 2010 Feb 28; 23(1):26-32. PubMed ID: 20040005 [Abstract] [Full Text] [Related]
13. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK. J Am Coll Cardiol; 2009 May 05; 53(18):1660-7. PubMed ID: 19406341 [Abstract] [Full Text] [Related]
18. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. Am Heart J; 2009 Oct 05; 158(4):520-526.e2. PubMed ID: 19781409 [Abstract] [Full Text] [Related]
20. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz KL, Massberg S, Schömig A, Kastrati A. Circ Cardiovasc Interv; 2011 Aug 05; 4(4):371-7. PubMed ID: 21791671 [Abstract] [Full Text] [Related] Page: [Next] [New Search]